on The Vanguard Group, Inc. (isin : US12572Q1058)
The Vanguard Group Discloses Position in Avadel Pharmaceuticals
On January 23, 2026, The Vanguard Group, Inc. disclosed its position in Avadel Pharmaceuticals plc as per Form 8.3 under the Irish Takeover Panel Act. This disclosure is essential for entities holding 1% or more of relevant securities in the context of takeovers. Vanguard Group controls 5,861,243 ordinary shares, equating to 6.02% ownership of Avadel Pharmaceuticals.
Recent transactions involved the purchase of 546 shares and the sale of 284 shares, both at a unit price of $21.53 USD. Vanguard reported no dealings in cash or stock-settled derivatives related to Avadel's securities.
No other agreements or arrangements were disclosed by Vanguard Group about indemnities or options related to the relevant securities, and the company confirmed no existing deals to refrain from future transactions in Avadel shares.
R. H.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all The Vanguard Group, Inc. news